Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study

Abstract Background Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated population....

Full description

Bibliographic Details
Main Authors: Josselin Annic, Hélène Babey, Romain Corre, Renaud Descourt, Gilles Quéré, Emmanuelle Renaud, Mickaël Lambert, Pierre Le Noac'h, Estelle Dhamelincourt, Jessica Nguyen, Alicia Vu, Vincent Bourbonne, Gilles Robinet, Margaux Geier
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
cerebral efficacy
epirubicin
paclitaxel
real life
small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.5143

Internet

https://doi.org/10.1002/cam4.5143

Similar Items